Cargando…
A flexible design for advanced Phase I/II clinical trials with continuous efficacy endpoints
There is growing interest in integrated Phase I/II oncology clinical trials involving molecularly targeted agents (MTA). One of the main challenges of these trials are nontrivial dose–efficacy relationships and administration of MTAs in combination with other agents. While some designs were recently...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899762/ https://www.ncbi.nlm.nih.gov/pubmed/31298770 http://dx.doi.org/10.1002/bimj.201800313 |